徐元庚老中医治疗肛肠疾病学术经验简介

徐元庚老中医是我院肛肠科奠基人之一,徐老年逾花甲,幼年攻读中医典籍,博采众长,徐老积40余年丰富临床经验对肛肠疾病治疗确有独到之处,发表论文40余篇,并编著《痔瘘疾病临床指南》一书。现就笔者往昔随师学习的点滴体会简述如下:1 熟读经旨,著书立说徐老出身于中医世家,幼承庭训,勤奋研读经典,深究其理,对《内经》、《伤寒》、《金匮》至今仍能背诵如流。在治学方面,主张志于医者,在熟读经典,而后逐步参悟经旨,阅读诸家医集,抱着实事求是的客观态度,掌握取长舍短,去粗存精的学习方法,以防食古不化,或断章取     

Effects ofTripterygium hypoglaucum (Lévl.) Hutch on male fertility

Tripterygium hypoglaucum (Lévl.) Hutch (TH) is a perennial used in Chinese traditional medicine for the treatment of rheumatoid arthritis and various skin disorders. One study showed that daily oral doses of TH significantly reduced the fertility of male rats without apparent toxicity. The effects of daily oral doses of TH on the fertility of men taking it for the treatment of rheumatoid arthritis were evaluated. Sperm concentration, motility and motility grade all were significantly reduced in the 13 men taking TH compared to 11 untreated controls. TH therapy did not affect testosterone, FSH, LH levels, and its antifertility effects appeared to be reversible.

---

Resumen Triperygium hypoglaucum (Lévl.) Hutch (TH) es una perenne usada en la medicina tradicional china para el tratamiento de artritis reumatoidea y de varios desórdenes de la piel. Un estudio demostró que orales diarias de TH reducían significativamente la fertilidad en ratas macho, sin toxicidad aparente. Se evaluaron los efectos de dosis diarias orales de TH en la fertilidad de hombres que le tomaban para el tratamiento de la artritis reumatoidea. La concentración de espermatozoides, la motilidad y el grado de motilidad, se encontraron significativamente reducidos en los 13 hombres tomando TH comparados con 11 controles no tratados. La terapia con TH no afectó los niveles de testosterona, FSH y LH y sus efectos antifertilidad parecían ser reversibles.

---

Resumé LeTriperygium hypoglaucum Hutch (TH) est communément utilisé en médecine traditionnelle chinoise pour le traitement de la polyarthrite chronique évolutive (PCE) et de divers troubles cutanés. Une étude a montré que l'administation quotidienne de doses orales de TH réduisait considérablement la fécondité de rats mâles sans provoquer de toxicité apparente. On a évalué les effets de doses quotidiennes administrées par voie orale sur la fécondité d'hommes atteints de PCE et traités au TH. La concentration, la motilité et le degré de motilité du sperme avaient significativement diminué chez 13 hommes traités au TH par comparaison avec 11 témoins non traités. Le traitement au TH n'a eu aucun effet sur les niveaux de testostérone, FSH et LH et ses effets anti-fécondants semblent être réversibles.

     

人碱性成纤维细胞生长因子基因在大肠杆菌中的克隆与表达

应用DNA重组技术将编码人碱性成纤维细胞生长因子（bbFGF）的基因克隆至原核高效表达质粒pBV_(221)的启动子下游。SDS-SAGE、ELISA和NTT活性监测结果表明:该重组质粒pBV-hbFGF在大肠杆菌DH5α中,经42℃诱导后,可表达出有较高生物活性的hbFGF。     

可调式外固定器治疗髌骨骨折50例报告

目的：介绍一种可调式外固定器，用于髌骨骨折的固定，可以早期功能锻炼。方法：既可开放复位穿针外固定，也可在透视下闭合穿针外固定。结果：本组50例，优28例，良20例，差2例。结论：该固定器操作简单，损伤小，免除第二次手术取固定器，是髌骨骨折外固定较佳器械。     

髌骨关节面的应用解剖学研究

本文利用150例髌骨(干燥髌骨100例,福尔马林固定膝关节内的髌骨50例)观测了髌骨关节面和关节软骨的形态及其与股骨内外侧髁关节面在屈膝0～135度范围的对应关系。结果发现中间纵嵴向后突起并由下向上逐渐变凸占100％;内侧纵嵴明显突起者占62％,此时其髌骨内侧部关节面与股骨关节面之间的间隙较大;在膝关节屈曲过程申两关节面接触的顺序为髌骨关节面自下而上、股骨内外侧关节面从前向后相对滑动,伸膝时则相反;髌骨关节面的表面积为1019±20(650～1540)mm~2。并讨论了髌骨关节面的解剖学特点及其临床意义。     

Graves病患者血清可溶性白介素2受体的探讨

对２８例Ｇｒａｖｅｓ病的可溶性白介素２受体（ｓＩＬ２Ｒ）和各种甲状腺激素以及甲状腺自身抗体治疗前后比较，并进行逐步回归，结果表明：治疗后Ｇｒａｖｅｓ病患者除ＴＳＨ外，各种甲状腺激素及甲状腺自身抗体显著降低（Ｐ＜００１），并对ｓＩＬ２Ｒ的上升与下降呈显著相关。     

A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart.

OBJECTIVE: To investigate the feasibility of intracoronary application of endothelial progenitor cells and the subsequent distribution within the heart. METHODS: Endothelial progenitors cells (EPCs) cultured from rat bone marrow were identified by double-positive staining with Dil-Ac-LDL and BS1-lectin. Twenty-four hours before cell transplantation, EPCs were labeled with 5-bromo-2'-deoxyuridine (BrdU). Cells (5 x 10(5) in 250-microl medium) were injected into healthy rats, either as intracoronary application (n=11) or as intramyocardial injection (n = 6). At 15 min or 3 days posttransplantation, hearts as well as other organs (lung, liver, kidney, and spleen) were collected and processed for subsequent BrdU immunohistochemistry. The number of BrdU-positive cells per tissue area was counted. RESULTS: Compared to intramyocardial injection, intracoronary administration resulted in more than twice as much positive cells in the heart (P < .05), with no local differences within the heart. Whereas after 15 min, EPCs were equally distributed in all examined organs (except for the spleen), cells that were still present after 3 days, approximately 10%, were selectively restricted to the heart. CONCLUSIONS: Our data indicate that the intracoronary application provides a promising technique for EPC transplantation in the rat heart.     

Effect of Renal Impairment on the Pharmacokinetics and Tolerability of Tiagabine

Summary: Purpose: We wished to determine the effect of renal impairment on the pharmacokinetics and tolerability of the new antiepileptic drug tiagabine (TGB).
Methods: We assessed TGB pharmacokinetics and tolerability in 25 subjects with various degrees of renal function (based on creatinine clearance, n = 4–6 per group) from healthy (group I) to requiring hemodialysis (group V) in a single and multiple dose (every 12h), one-period (groups I-IV) or a single dose, two-period (group V) study (4-mg oral doses of TGB · HCl). Blood samples were collected after the first dose (both periods for group V) and after the last dose on day 5 (groups I-IV). TGB plasma concentrations and plasma protein binding were determined by high-performance liquid chromatography (HPLC) and ultrafiltration, respectively.
Results: TGB was well tolerated by all study subjects. The pharmacokinetics of TGB were similar in all subjects; no pharmacokinetic parameter (based on either total or unbound concentrations) was statistically correlated with creatinine clearance. For total TGB in plasma, single-dose mean values of the maximum plasma concentration, clearance, and half-life (t1/2) ranged from 52 to 108 ng/ml, from 7.14 to 11.02 I/h, and from 6.4 to 8.4 h, respectively.
Conclusions: TGB pharmacokinetics and tolerability were independent of renal function; therefore, dosage adjustment is unnecessary for epilepsy patients with renal impairment.